DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.
Generic Entry Opportunity Date for 204677
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 204677
|Mechanism of Action||Positron Emitting Activity |
Suppliers and Packaging for NDA: 204677
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||SOLUTION;INTRAVENOUS||Strength||30ML (1.4-135mCi/ML)|
|Approval Date:||Mar 19, 2014||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Mar 21, 2019|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||Start Trial||Patent Expiration:||Mar 18, 2029||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patented Use:||NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT|
Complete Access Available with Subscription